NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that results from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in large ischemic strokes will be presented during two oral presentations at the upcoming International Stroke Conference (ISC) 2016, being held February 17-19, 2016 at the Los Angeles Convention Center in Los Angeles, California.
The two oral presentations will be conducted by principal investigators and leading neuroscience researchers at Yale University and Massachusetts General Hospital.
“We are thrilled to have this exciting data presented to a group of illustrious clinicians at the world’s largest and most prestigious medical meeting dedicated to the science and treatment of cerebrovascular disease,” commented Sven Jacobson, CEO of Remedy Pharmaceuticals. “Edema is one of the most significant mortality risks associated with stroke and other acute CNS conditions. In fact, in the first week following an ischemic stroke, 78% of all deaths are attributable to edema and in hemorrhagic stroke, 93% of deaths are caused by this type of swelling. CNS edema continues to be a condition characterized by major unmet medical need. We look forward to sharing the full results of the Phase 2 trial evaluating CIRARA for reduction of the devastating consequences associated with edema after a severe stroke.”
Logistical details for the two oral presentations include:
Abstract LB6: GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: A Phase II Study Toward Preventing Edema After Ischemia
Presenting Author: Kevin N. Sheth, MD, FAHA, FCCM, FNCS, FAAN, FANA
Associate Professor of Neurology and of Neurosurgery
Division Chief, Neurocritical Care and Emergency Neurology;
Director, Neuroscience ICU;
Chief, Clinical Research, Department of Neurology;
Yale University, New Haven, CT
Session: A34 – Late-Breaking Science Oral Abstracts I
Date: Wednesday, February 17, 2016
Time: 4:06 – 4:18 pm PT
Location: Room 408
Abstract LB24: GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP: Intermediate Endpoint Analysis as Proof-of-Concept
Presenting Author: W. Taylor Kimberly, MD, PhD
Associate Director, Neuroscience Intensive Care Unit;
Massachusetts General Hospital;
Assistant Professor of Neurology;
Harvard Medical School, Boston, MA
Session: Plenary Session III
Date: Friday, February 19, 2016
Time: 12:17 – 12:29 pm PT
Location: Hall K
Remedy will be available to meet with potential Phase 3 clinical sites and other interested parties at Booth # 629 in the Science and Technology (Exhibit) Hall.
The International Stroke Conference is the world’s largest medical meeting dedicated to the science and treatment of cerebrovascular disease. This 2½-day conference features more than 1,500 presentations that emphasize basic, clinical and translational sciences as they evolve toward a more complete understanding of stroke pathophysiology with the overall goal of developing more effective prevention and treatment.
CIRARA™ is a patented, high affinity inhibitor of Sur1-Trpm4 channels suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to millions of people affected by acute central nervous system (CNS) edema – including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.
Contact: Remedy Pharmaceuticals Sven Jacobson 212-586-2226 x 225 email@example.com Investors Lee Roth / Tram Bui, The Ruth Group 646-536-7012 / 646-536-7035 firstname.lastname@example.org / email@example.com Media Kirsten Thomas, The Ruth Group 508-280-6592 firstname.lastname@example.org